Cell and gene medicine can produce life-changing therapies for patients suffering from incurable diseases. The ARM Foundation for Cell and Gene Medicine is dedicated to providing the education, information, and research needed to accelerate patient awareness of and access to these transformative therapies.

The Foundation is an independent, 501(c)(3) non-profit organization established in 2018 by the Alliance for Regenerative Medicine (ARM), the preeminent international advocacy organization for regenerative medicine and advanced therapies.


The goal of the ARM Foundation for Cell and Gene Medicine is to educate, engage, and empower patients, caregivers, industry leaders, and other stakeholders to help advance the science and benefits of gene therapy, gene editing, cell therapy, tissue-engineering and organ regeneration. It will accomplish this through educational and research projects that increase public awareness of the clinical and social benefits of gene medicine, which will help to expedite the development of life-saving therapies.


The ARM Foundation serves as the educational and information catalyst on issues fundamental to making gene and cell therapies, tissue-engineered products and other regenerative medicine treatments available to patients.

By examining, quantifying, clarifying and informing stakeholders of the clinical and societal benefits of these therapies, as well as convening discussions to raise awareness about the sector’s progress, challenges and results, the Foundation accelerates patient access to safe, efficacious and potentially curative therapies.




Board of Directors


Nicole Boice, Co-Founder and Executive Director, RARE-X

Cindy Collins, CEO, Editas Medicine

Amy Duross, CEO, Vineti

Don Gibbons, Consultant, DLG Strategic Communication

Ellen Feigal, Partner, NDA Partners, former SVP R&D for CIRM

Alison Finger, SVP Marketing, bluebird bio

Pat Furlong, Founding President and CEO, Parent Project Muscular Dystrophy

Brett Kopelan, Executive Director, debra of America

Alexandra Levine, Chief Medical Officer, City of Hope

Michael May, CEO, CCRM

Adrian McKemey, Managing Director Quintiles IQVIA, Founder, Quintiles Consulting

Maria T. Millan, President and CEO, California Institute for Regenerative Medicine (CIRM)

David Nagler, Formerly of Audentes

Stewart Parker, Principal, Parker BioConsulting

Matt Patterson, Strategic Advisor, Audentes, an Astellas Company

Dennis Purcell, Founder, Senior Advisor, Aisling Partners

Brock Reeve, Executive Director, Harvard Stem Cell Institute

Martha Rook, Senior Vice President and Head of Manufacturing, Sigilon Therapeutics, Inc.

Morrie Ruffin, Executive Director, ARM Foundation

Frank Sasinowski, Director, Hyman, Phelps & McNamara

Bob Smith, Senior Vice President, Global Gene Therapy, Pfizer

David Smith, Of Counsel, Pepper Hamilton, LLP

Robin Smith, Stem for Life Foundation and Cura Foundation

Jennifer Mound Smoter, SVP, External Affairs & Communications, Intellia Therapeutics

Phil Vanek, General Manager, Cell Therapy, GE Healthcare Life Sciences

Michael Werner, Co-Founder and Senior Policy Counsel, Alliance for Regenerative Medicine

Claudia Zylberberg, CEO, Akron Biotech




Morrie Ruffin
Executive Director

Bethany Kraynack
Finance & Operations

Adam Roose
Senior Advisor

Heather Brown
Senior Advisor

Jennifer Braswell, PhD
Senior Advisor

Erin Cummings
Executive Assistant


The ARM Foundation for Cell & Gene Medicine is seeking qualified candidates for the role of Executive Director. Find out more here!






The ARM Foundation for Cell and Gene Medicine relies on Steering Committees to guide vital program planning, implementation, and performance. Their role in creating value to all stakeholders is critical to the transformation of medicine, and we are grateful for their ongoing contributions.




Phil Vanek, PhD
General Manager, Cell Bioprocessing, GE Healthcare

Cindy Collins, MBA
Board of Directors, Triumvira Immunologics

Alison Finger, MBA
Chief Commercial Officer, Bluebird Bio

Amy Duross, MBA
Co-Founder and Chief Executive Officer, Vineti

Claudia Zylberberg
PhD, Co-Founder and Chief Executive Officer, Akron Biotech

Jerry Keybl
PhD, Head of Cell & Gene Therapy Manufacturing Franchise, MilliporeSigma

Michael May
PhD, Chief Executive Officers, Centre for Commercialization of Regenerative Medicine

Bruce Levine
PhD, Barbara and Edward Netter Professor in Cancer Gene Therapy, University of Pennsylvania

Jill Maddux
Head of Cell and Gene Therapy Product Strategy, McKesson Life Sciences

Eric Roos
PhD, Strategic Alliances Leader Cell Therapy, Thermo Fisher Scientific

Isabelle Riviere
PhD, Director Michael G. Harris Cell Therapy and Cell Engineering Laboratory, MSKCC

Bruce Thompson
PhD, Vice President of Process Sciences, Lyell Immunopharma

Alberto Santagostino
MBA, SVP & Head of Cell and Gene Technology, Lonza

Bob Preti
PhD, Chairman, CEO & President, Hitachi Chem Advanced Therapeutic Solutions; General Manager, HCC Regenerative Medicine Business

Vijai Mohan
Life Sciences Executive, Arcline Investment Management

Chirs Vann
Chief Operating Officer, Autolus Ltd




John Doyle, Dr.P.H., MPH
Senior Vice President and General Manager, Quintiles INQVIA

Peter Neumann, ScD
Director, Center for the Evaluation of Value and Risk in Health at the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center; Professor of Medicine, Tufts University School of Medicine

Eric Faulkner, MPH
Vice President and Executive Director, Real-World Value and Strategy, Center of Excellence for Precision and Transformative Technology, Evidera

Ron Bartek
President/Director/Co-Founder, FARA

Sean Tunis, MD, MSc
Founder and Chief Executive Officer, Center for Medical Technology Policy

David Smith, JD
Of Counsel, Pepper Hamilton, LLP

Scott Riccio, MBA
Head of Advocacy, Juno Therapeutics

Matthew Durdy
Chief Business Officer, Gene and Cell Therapy, UK Catapult

Dennis Purcell, MBA
Founder and Senior Advisor, Aisling Capital

Brock Reeve, MPhil, MBA
Executive Director, Harvard Stem Cell Institute

Jim Lennertz Jr.
Vice President and General Manager EUMEA, BioMarin




Nicole Boice, Founder
Global Genes

Max Bronstein
Senior Director, Health Policy & Public Affairs, Audentes

Jill Dolgin
Head of Patient Advocacy, AGTC

Stephanie Fagan
SVP Corporate Communications, bluebird bio

Elisabeth Fine, PhD, CMPP
Senior Director, Medical Affairs & Operations, Voyager Therapeutics

Betsy Foss-Campbell, MA
Senior Manager of Advocacy and Outreach, American Society of Gene & Cell Therapy

Don Gibbons
Former Head of Communications at CIRM, now consultant

Chelsey Hathaway
Director, Patient Engagement, ARM

Tim Hunt
SVP, Corporate Affairs, Editas Medicine

Heather King, PhD
Director of Marketing Communications and PR, Precision BioSciences

Maureen McArthur Hart, PhD
Strategic Advisor, Medical and Scientific Advisory Board, Global Genes

Megan McGill, MD, PhD
Director, Corporate Affairs, REGENEX BIO

Emily McGinnis
VP, Marketing, AveXis

Matt Might
Director, Hugh Kaul Precision Medicine Institute, Univ Alabama at Birmingham

Christeen Moburg
Sr. Director Patient Advocacy, Sangamo Therapeutics (Co-Chair)

Lyndsey Scull
VP, Communications, ARM

Jennifer Mound Smoter
SVP, External Affairs & Communications, Intellia Therapeutics

Susan Sikora-Brisendine
Patient Engagement, Global Genes (Co-Chair)

Gary Surmay
Senior Director, US Public Affairs – Rare Disease, Pfizer